Prevention and treatment of sepsis
AssigneePromega Corporation
InventorSean B. Carroll
Life of this patent
Estimating the term…
Abstract
Compositions and methods are described for preventing and treating sepsis in humans and animals. Surgical patients, low birth weight infants, and burn and trauma victims can be treated prophylactically. Methods for treating acute infections are provided with advantages over current therapeutic approaches.
Claims32
An antibiotic-antibody conjugate, comprising surface-active antibiotic covalently bound via a non-carbodiimide cross-linker to non-specific immunoglobulin having an Fc region wherein said conjugate binds to bacteria via said antibiotic.
An antibiotic-antibody conjugate, comprising an endotoxin-binding compound covalently bound via a cross-linker to non-specific immunoglobulin having an Fc region.
A therapeutic preparation, comprising surface-active antibiotic covalently bound via a cross-linking spacer to non-specific immunoglobulin G, wherein said preparation is bactericidal for both gram-positive and gram-negative organisms, and wherein said preparation after administration demonstrates a circulating serum half-life greater than twenty days.
A method of treatment, comprising:
- a) providing a mammal for treatment;
- b) providing a therapeutic preparation, comprising a surface-active antibiotic covalently bound via a non-carbodiimide crosslinker to non-specific immunoglobulin;
- and
- c) administering said preparation to said mammal, prior to any symptoms of bacterial infection.
A therapeutic preparation comprising a mixture of:
- i) a first conjugate comprising a first antibiotic covalently bound to non-specific immunoglobulin G;
- and ii) a second conjugate comprising a second antibiotic covalently bound to non-specific immunoglobulin G, wherein said preparation after administration demonstrates a circulating serum half-life greater than twenty days.
Dependencies are inferred from the claim text.